Abstracts tagged "biomarkers and rheumatoid arthritis (RA)"

Abstract Number: 89 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Genome-Wide Association Study of Anti-Tumor Necrosis Factor Response Among Japanese Patients with Rheumatoid Arthritis
Kyoko Honne¹, Ingileif Hallgrimsdottir², Chunsen Wu³, Ronnie Sebro⁴, Nicholas Jewell², Takeo Sakurai⁵, Masahiro Iwamoto⁶, Seiji Minota⁶ and Damini Jawaheer⁷, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ²UC Berkeley, Berkeley, CA, ³University of Southern Denmark, Odense, Denmark, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Inoue Hospital, Takasaki, Japan, ⁶Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁷Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Studies of patients with rheumatoid arthritis (RA) to identify genetic biomarkers of anti-tumor necrosis factor (TNF) response have been conducted mostly in Caucasian populations.…
Abstract Number: 491 • 2015 ACR/ARHP Annual Meeting
A Paradigm Shift in the Disease Assessment of Rheumatoid Arthritis : From Blood to Urine Testing
Wan-Uk Kim¹, Yune-Jung Park², Seung-Ah Yoo³, Bong Ki Hong³, Gi myo Kim⁴, Susanna Choi⁵, Saseong Lee³ and Chul-Soo Cho⁶, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea, ³Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea, ⁴Institute of bone and joint diseases, Catholic university, seoul, South Korea, ⁵Institute of Bone and Joint diseases, The Catholic University of Korea, seoul, South Korea, ⁶Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: To optimize treatment for rheumatoid arthritis (RA), it is ideal to monitor disease activity on a daily basis such as glucose measurement since RA…
Abstract Number: 607 • 2015 ACR/ARHP Annual Meeting
Serum Progranulin (PRGN) Level Is Not a Biomarker for Responsiveness to Tumor Necrosis Factor (TNF)-Antagonist Therapy in Rheumatoid Arthritis (RA) Patients
Rosy Rajbhandary¹, Rebekah Neal², Jennifer Johnson³, Qingyun Tian⁴, Jinlong Jian⁵, Chuanju Liu⁶ and William Stohl², ¹Medicine/Rheumatology, LAC+ USC Medical Center, Los Angeles, CA, ²Div of Rheumatology, USC, Los Angeles, CA, ³Medicine, Keck School of Medicine of USC, Los Angeles,, CA, ⁴Nyu,Hid,301 E 17th St, New York University Medical Center, New York, NY, ⁵301 E. 17th St., Rm 1600, New York, NY, ⁶NYU Hospital for joint Diseases, New York, NY
Background/Purpose: PRGN is a growth factor that binds TNF receptors without triggering TNF-like activity, thereby serving as a naturally-occurring antagonist of TNF -mediated inflammatory signaling.…
Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…
Abstract Number: 1244 • 2015 ACR/ARHP Annual Meeting
Extracellular MicroRNAs in Synovial Fluid Reveal a Marked Proliferative Signature in Patients with Antibiotic-Refractory Lyme Arthritis
Robert B. Lochhead, Nancy D. Kim, Sheila Arvikar, Klemen Strle and Allen C. Steere, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA), caused by a tick-borne spirochete Borrelia burgdorferi, usually resolves appropriately with antibiotic treatment, called antibiotic-responsive LA. However, in some patients, arthritis…
Abstract Number: 1571 • 2015 ACR/ARHP Annual Meeting
How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis?
Andrew Holman¹ and Edmund Ng², ¹Inmedix, Normandy Park, WA, ²Statistical Thinking, Seattle, WA
Background/Purpose: As rheumatologists search for new targets to improve immunosuppressive outcomes, the autonomic nervous system (ANS) as a co-factor in autoimmune disease expression has gained…
Abstract Number: 1680 • 2015 ACR/ARHP Annual Meeting
Selective JAK1 Inhibition with Filgotinib (GLPG0634) Decreases Plasma Markers of Inflammation and Joint Damage in Patients with Rheumatoid Arthritis
René Galien¹, Annegret Van der Aa², Roland Blanque¹, Sophie Darquenne¹, Pille Harrison² and Chantal Tasset², ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Among the 4 Janus kinase (JAK) family members, JAK1 often has a dominant role in the intracellular signaling for cytokines involved in auto-immune and…
Abstract Number: 2781 • 2015 ACR/ARHP Annual Meeting
Absence of Effects of Filgotinib on Erythrocytes, CD8+ and NK Cells in Rheumatoid Arthritis Patients Brings Further Evidence for the JAK1 Selectivity of Filgotinib
René Galien^1,2, Reginald Brys³, Annegret Van der Aa³, Pille Harrison³ and Chantal Tasset³, ¹Galapagos SASU, Romainville, France, ²102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: The distinct role of JAK family members (JAK1, JAK2, JAK3 and TYK2) in signaling for cytokines and growth factors has established these kinases as…
Abstract Number: 2086 • 2014 ACR/ARHP Annual Meeting
Replication of PTPRC As Genetic Biomarker of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis
Antonio Gonzalez¹, Aida Ferreiro-Iglesias², Juan Gomez-Reino³ and on Behalf of Their Collaborators⁴, ¹Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Insitituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁴multiple, multiple, Spain
Background/Purpose The use of biomarkers to predict response to the different drugs available for treating rheumatoid arthritis (RA) is a very desirable goal. However, success…
Abstract Number: 2020 • 2014 ACR/ARHP Annual Meeting
Circulating Carotenoids and Subsequent Risk of Rheumatoid Arthritis
Yang Hu¹, Karen H. Costenbader², Elizabeth W. Karlson² and Bing Lu², ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antioxidant components in food may be biologically relevant to the prevention of rheumatoid arthritis (RA). Evidence from prospective cohort studies regarding the relationship between…
Abstract Number: 409 • 2014 ACR/ARHP Annual Meeting
Soluble CD163 Is a Marker of Disease Activity in Early Rheumatoid Arthritis and Reflects TNFα Levels
Stinne Greisen¹, Holger Jon Møller², Kristian Steengaard-Petersen³, Merete Lund Hetland⁴, Kim Hoerslev-Petersen⁵, Peter Junker⁶, Mikkel Ostergaard⁷, Malene Hvid¹ and Bent Deleuran¹, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁵Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁶Odense University Hospital, Odense, Denmark, ⁷Copenhagen University Hospital at Glostrup, Copenhagen, Denmark
Background/Purpose Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and eventually destruction, where TNFa is a central mediator of both processes.…
Abstract Number: 404 • 2014 ACR/ARHP Annual Meeting
The Relationship Between Disease Activity and Levels of HMGB1 in Patients with Rheumatoid Arthritis
David S. Pisetsky^1,2, Diane Spencer³, Stephen R. Wisniewski⁴, Jason Lyons⁴, Melissa Saul⁵, Mandy J. McGeachy⁶, Yong Gil Hwang⁷, Heather Eng⁴ and Larry W. Moreland⁶, ¹Medical Research Service, Durham VAMC, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Medicine, Duke University Medical Center, Durham, NC, ⁴Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Biomedical Informatics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, ⁶Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose HMGB1 (High Mobility Group Box 1), a non-histone nuclear protein, is a prototypic alarmin that displays immunological activity following release during cell death or…
Abstract Number: 367 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying…
Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting
Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
Sophine B. Krintel¹, Christian Dehlendorff², Merete Lund Hetland³, Kim Hørslev-Petersen⁴, Klaus K. Andersen², Peter Junker⁵, Jan Pødenphant⁶, Torkell Ellingsen⁷, Palle Ahlqvist⁸, Hanne M. Lindegaard⁹, Asta Linauskas¹⁰, Annette Schlemmer¹¹, Mette Y. Dam¹², Ib Hansen¹³, Hans Chr Horn¹⁴, Anette Jørgensen¹⁵, Johnny Raun¹⁶, Christian G. Ammitzbøll¹², Mikkel Østergaard¹⁷, Kristian Stengaard-Pedersen¹² and Julia S. Johansen¹⁸, ¹Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ⁵University of Southern Denmark, Odense, Denmark, ⁶Copenhagen University at Gentofte, Hellerup, Denmark, ⁷Silkeborg Regional Hospital, Silkeborg, Denmark, ⁸University of Southern Denmark, Vejle, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁰Vendsyssel Hospital, Hjørring, Denmark, ¹¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹²Arhus University Hospital, Aarhus, Denmark, ¹³Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁴Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁵Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹⁶University of Southern Denmark, Graasten, Denmark, ¹⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ¹⁸Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark
Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…
Abstract Number: 478 • 2013 ACR/ARHP Annual Meeting
Analysis Of The JAK1 Selectivity Of GLPG0634 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients
René Galien¹, Béatrice Vayssière¹, Steve de Vos², Marielle Auberval¹, Nick Vandeghinste², Sonia Dupont¹, Philippe Clément-Lacroix¹, Philippe Delerive¹, Frédéric Vanhoutte², Reginald Brys², Annegret Van der Aa², Luc Van Rompaey² and Gerben van 't Klooster², ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that transduce intracellular signaling for cytokines including interleukins and interferons, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.